Cases & Deals

  • Home
  • Practices
  • ToolGen defends multi-party opposition at EPO relating to CRISPR/Cas9 gene editing technology

Share

ToolGen defends multi-party opposition at EPO relating to CRISPR/Cas9 gene editing technology

September 2018

Client(s) ToolGen, Inc.

Jones Day is acting for ToolGen, Inc. in defense of a multi-party opposition filed at the European Patent Office against its patent rights covering application of the revolutionary CRISPR/Cas9 gene editing technology in biotechnology, medicine, and agriculture.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.